Bronchogen (AEDL): The Khavinson Bronchopulmonary Tetrapeptide — Complete Research Profile

# Bronchogen (AEDL): The Khavinson Bronchopulmonary Tetrapeptide — Complete Research Profile

What Is Bronchogen?

Bronchogen is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Its amino acid sequence — Alanine-Glutamic acid-Aspartic acid-Leucine (AEDL) — was derived from bronchial epithelial tissue, where it was identified as a tissue-specific signaling molecule with a demonstrable role in regulating lung cell gene expression and epigenetic architecture.

Within the Khavinson peptide bioregulator family, Bronchogen occupies a distinct niche: it is the primary bronchopulmonary bioregulator, designed for cell biology research focused on airway epithelium, mucociliary function, pulmonary surfactant biology, and respiratory aging. Unlike receptor agonists or enzymatic inhibitors that act through pharmacological target engagement, Khavinson bioregulators like Bronchogen operate through direct interaction with DNA promoter regions and chromatin-associated proteins, modulating transcriptional programs in a tissue-preferential manner.

This profile documents Bronchogen's structural characteristics, its verified mechanisms of gene regulation, research findings from peer-reviewed studies, and its context within the broader framework of bronchopulmonary biology research.

> Research Use Only. Bronchogen is a research chemical intended exclusively for in vitro and preclinical laboratory investigation. This article contains no clinical recommendations, dosing guidance for humans or animals, or therapeutic claims. All information is provided strictly for scientific education.

---

Structural Profile

The tetrapeptide configuration of Bronchogen places it in the class of ultrashort bioregulators — compounds small enough to achieve efficient cellular and nuclear penetration while retaining the structural specificity required for selective interaction with nucleic acid grooves and histone protein domains. Its mixed composition of two acidic residues (glutamic acid and aspartic acid) flanked by a small hydrophobic residue (alanine) and a bulkier hydrophobic terminal (leucine) confers a dual capacity for electrostatic interaction with positively charged histone domains and hydrophobic insertion into DNA grooves.

---

The Khavinson Bioregulator Framework

To fully appreciate Bronchogen's research context, it is essential to understand the conceptual framework from which it emerged. Beginning in the 1970s, Vladimir Khavinson proposed that biological aging involves progressive dysregulation of gene expression across tissues — a decline that may be partly reversible through the administration of tissue-derived short peptides that restore normal transcriptional patterns.

The foundational hypothesis holds that these short peptides, originally isolated from organ-specific tissue extracts, carry structural information that enables them to interact preferentially with promoter regions relevant to their tissue of origin. Over decades of systematic research, Khavinson and collaborators synthesized pure versions of these peptides and characterized their effects in vitro, in animal models, and in limited clinical investigations.

Published findings across the Khavinson peptide family have documented:

• •Geroprotective effects in rodent models, including extended mean and maximum lifespans and reduced tumor incidence (Anisimov & Khavinson, 2010, PMID 19830585)
• •Tissue-specific gene regulation in cell culture systems
• •Epigenetic mechanisms involving histone binding and chromatin remodeling
• •Telomere biology effects, with some peptides activating telomerase expression

A 2021 systematic review in Molecules comprehensively analyzed the gene regulatory evidence across the bioregulator family, including Bronchogen, cataloging its specific target genes and molecular interaction data (Khavinson et al., 2021, PMID 34834147).

Bronchogen sits among a growing catalog of tissue-specific Khavinson bioregulators that have been characterized in published research, including Epitalon (pineal tetrapeptide), Pinealon (EDR tripeptide), Vilon (thymic dipeptide), Vesugen (vascular tripeptide), Cardiogen (cardiac tetrapeptide), and Testagen (testicular tetrapeptide). Bronchogen is the bronchopulmonary member of this family.

---

Mechanism of Action

DNA Groove Binding

Physical chemistry studies have characterized Bronchogen's interaction with double-stranded DNA using spectrophotometry, viscometry, and circular dichroism. Research published in the Bulletin of Experimental Biology and Medicine demonstrated that Bronchogen (AEDL) functions as a DNA-stabilizing agent, increasing DNA melting temperature by approximately 3.1°C at molar ratios of 0.01–0.055 ([Monaselidze et al., 2011,]()).

Binding analysis indicated that AEDL interacts with both DNA strands primarily through contacts with nitrogen bases. Notably, the peptide does not show adenine-thymine or guanine-cytosine specificity, suggesting a binding modality that achieves structural stabilization through a mechanism distinct from typical intercalating or groove-binding small molecules. The 2021 systematic review further noted that AEDL can interact with the major groove of dsDNA, forming contacts with the N7 and O6 atoms of guanine — structural interactions consistent with transcriptional modulation in promoter regions.

Chromatin Remodeling via Histone Binding

Work by Fedoreyeva, Vanyushin, and Baranova published in AIMS Biophysics demonstrated that AEDL alters chromatin conformation through specific binding to histone proteins (Fedoreyeva et al., 2020, DOI 10.3934/biophy.2020001).

Using fluorescence quenching experiments with FITC-labeled histones, the researchers showed that AEDL binds to linker histone H1 and the core H3-H1-DNA complex in a 1:1 molar ratio. Binding sites were localized to the N-terminal lysine residue of H1 and the lysine residue at position 36 of the H3 C-terminus. At a concentration of 10⁻⁷ M, AEDL reduced condensed chromatin domains from 45% in control cells to 25%, effectively promoting the formation of transcriptionally active euchromatin.

This mechanism — histone binding leading to chromatin decondensation and gene activation — is consistent with a geroprotective model in which declining transcriptional activity in aging cells can be partially restored through targeted epigenetic intervention.

Target Gene Regulation in Bronchial Epithelium

The most detailed bronchopulmonary gene expression research was published in Lung in 2014 by Khavinson and a multidisciplinary team ([Khavinson et al., 2014,]()). Using human embryonic bronchoepithelial cell cultures and real-time PCR methodology, the study documented that AEDL regulates expression of a cluster of genes critical to bronchial epithelium identity and function:

• •NKX2-1 (TTF-1): The master transcription factor for lung specification and alveolar type II cell differentiation
• •SCGB1A1 (CC16/CC10): Club cell secretory protein, a key immunomodulatory protein of the airway epithelium
• •SCGB3A2: A club cell-expressed secretoglobin implicated in anti-inflammatory and anti-fibrotic processes
• •FOXA1 and FOXA2 (HNF3α/β): Forkhead box transcription factors essential for lung development, branching morphogenesis, and surfactant gene regulation
• •MUC4 and MUC5AC: Transmembrane and gel-forming mucins governing airway mucosal integrity and barrier function
• •SFTPA1: Surfactant protein A, a collectin molecule that reduces alveolar surface tension and mediates innate immune defense at the air-liquid interface

The coordinated upregulation of this gene set represents a coherent biological response: AEDL appears to activate a transcriptional program associated with airway epithelial identity, barrier competence, mucociliary function, and surfactant homeostasis — precisely the functional domains that decline during bronchial aging and in chronic lung conditions studied in research models.

Additionally, the 2014 study found that AEDL demonstrated its strongest effects on cell proliferation markers (including Ki67 and Mcl-1) in aged cell cultures, suggesting an enhanced responsiveness in senescent bronchial cells — a pattern consistent with the geroprotective hypothesis.

---

Key Research Studies

Study 1: Gene Expression in Bronchial Epithelium (2014)

Reference: Khavinson VKh et al. Lung 192(5):781-791, 2014. []()

Model: Human embryonic bronchoepithelial cell cultures

Method: Real-time PCR, immunocytochemistry, DNA-binding spectroscopy

Key findings:

• •AEDL activated NKX2-1, FOXA1, FOXA2, SCGB1A1, SCGB3A2, MUC4, MUC5AC, and SFTPA1 expression
• •Physical analysis confirmed AEDL-DNA interaction in the major groove
• •Strongest proliferative effects observed in aged cell cultures
• •Authors proposed AEDL may protect bronchial epithelium from pulmonary pathology and provide geroprotective effects

Research significance: This study establishes the foundational mechanistic link between AEDL and bronchial epithelial biology, identifying a coherent and functionally relevant gene regulatory program.

---

Study 2: DNA Stabilization Properties (2011)

Reference: Monaselidze JR et al. Bull Exp Biol Med 150(3):375-377, 2011. []()

Model: Isolated DNA in vitro (biophysical characterization)

Method: Calorimetry, DNA melting analysis

Key findings:

• •Bronchogen (AEDL) increased DNA melting temperature by 3.1°C at defined molar ratios
• •Strong and occasional binding occurs with both DNA strands
• •Not adenine-thymine or guanine-cytosine specific — binding through nitrogen base contacts
• •Functions as a thermostabilizing agent for the DNA double helix

Research significance: Provides the biophysical basis for understanding how ultrashort peptides can exert gene regulatory effects through direct nucleic acid interaction rather than protein receptor intermediaries.

---

Study 3: Chromatin Conformation via Histone Binding (2020)

Reference: Fedoreyeva LI, Vanyushin BF, Baranova EN. AIMS Biophysics 7(1):1-16, 2020. DOI 10.3934/biophy.2020001

Model: Nicotiana tabacum (plant chromatin model system)

Method: Fluorescence quenching, confocal microscopy

Key findings:

• •AEDL at 10⁻⁷ M reduced condensed chromatin from 45% to 25%
• •Binds histone H1 (N-terminal lysine) and H3 (lysine-36) in 1:1 molar ratio
• •Promotes formation of transcriptionally active euchromatin
• •Mechanism involves histone-DNA relaxation rather than direct transcription factor recruitment

Research significance: Establishes the epigenetic mechanism by which AEDL modulates gene expression — chromatin decondensation through specific histone protein contacts, opening genomic regions to transcriptional machinery.

---

Study 4: Inflammatory Pathway Regulation (2022)

Reference: Avolio F, Martinotti S, Khavinson VK et al. Int J Mol Sci 23(7):3607, 2022. PMID 35408963

Model: Human monocytic THP-1 cell line (differentiated to macrophages)

Method: Cell proliferation assays, TNF production analysis, adhesion studies

Key findings (Bronchogen/Chonluten context):

• •Multiple Khavinson peptides, including the related bronchial bioregulator Chonluten, demonstrated inhibition of TNF production in LPS-stimulated monocytes
• •Chonluten showed downregulation of cell-cell adhesion mechanisms between monocytes and endothelial cells
• •Unique behavior in monocytic function regulation, including effects on apoptosis and proliferation

Research significance: Demonstrates that Khavinson bronchopulmonary bioregulators possess immunomodulatory properties beyond direct epithelial effects, relevant to research into pulmonary inflammation and innate immunity.

---

Study 5: Systematic Review of Peptide Gene Regulation (2021)

Reference: Khavinson VKh et al. Molecules 26(22):7053, 2021. PMID 34834147

Type: Systematic review of Khavinson bioregulator gene regulation evidence

Coverage: 35+ years of peptide bioregulator research

Key findings:

• •AEDL interaction with DNA major groove confirmed (N7 and O6 positions of guanine)
• •Binding to histones H1, H2B, H3, H4 documented, with peptide-binding motifs in N-terminal histone regions
• •AEDL classified as stimulating lung cell differentiation and activating a specific transcriptional program
• •MUC4, MUC5AC, SFTPA1, and developmental transcription factors identified as target genes

Research significance: Provides the most comprehensive mechanistic overview of AEDL's gene regulatory activity and positions it within the broader framework of peptide epigenomics research.

---

Study 6: Growth Promotion and Glutathione Regulation (2024)

Reference: Kononenko NV, Fedoreyeva LI. Int J Mol Sci 26(1):289, 2024. []()

Model: Nicotiana tabacum (plant model system)

Method: Root growth analysis, gene expression, glutathione quantification

Key findings:

• •AEDL increased total plant biomass 1.7-fold compared to controls
• •Glutathione content in roots increased 3.24-fold
• •Activated expression of GSH1 and GSH2 genes (glutathione synthesis pathway)
• •Protected root epithelial cells under salt stress conditions through ROS-redox signaling

Research significance: Extends understanding of AEDL's cellular protective mechanisms to include redox regulation and stress resistance pathways — relevant to bronchial epithelial models where oxidative stress is a key pathogenic driver.

---

Target Gene Biology: What the Research Program Reveals

The genes activated by Bronchogen (AEDL) in bronchial epithelial research represent a coherent biological network. Understanding each gene's function provides scientific context for why this activation pattern is considered relevant to bronchopulmonary research:

NKX2-1 (Thyroid Transcription Factor 1 / TTF-1)

NKX2-1 is the master regulator of lung identity. It is expressed in type II alveolar cells and bronchiolar club cells, where it controls surfactant protein genes (SFTPA, SFTPB, SFTPC, SFTPD), airway secretoglobins, and branching morphogenesis. Loss of NKX2-1 expression correlates with dedifferentiation and pulmonary pathology in research models.

FOXA1 and FOXA2 (Forkhead Box A1/A2)

These pioneer transcription factors open compacted chromatin at lung gene promoters, enabling expression of differentiation-associated genes including surfactants, mucins, and secretory proteins. FOXA2 is particularly critical for alveolar development and the airway epithelial response to injury. Both are expressed throughout the respiratory epithelium from the trachea to the alveoli.

SCGB1A1 and SCGB3A2 (Secretoglobins)

Club cells (formerly Clara cells) of the bronchiolar epithelium secrete SCGB1A1 (CC16/uteroglobin) and SCGB3A2 as immunomodulatory proteins. CC16 has demonstrated anti-inflammatory properties in multiple lung disease research models, and declining SCGB1A1 expression is associated with aging airways.

MUC4 and MUC5AC (Mucins)

MUC4 is a transmembrane mucin that forms part of the epithelial glycocalyx and contributes to mucociliary defense mechanisms. MUC5AC is the primary gel-forming mucin of the airway goblet cell, central to mucus layer formation. Both are subjects of active research in models of chronic airway disease.

SFTPA1 (Surfactant Protein A)

Surfactant protein A is a collectin that reduces alveolar surface tension while simultaneously engaging innate immune pathways in the alveolar space. Its expression is critically regulated by NKX2-1, FOXA2, and TTF-1, placing SFTPA1 downstream in the same transcriptional hierarchy that AEDL appears to activate.

---

Bronchogen in the Context of Aging Lung Biology Research

Pulmonary aging is characterized by progressive changes in airway and alveolar structure: loss of elastic recoil, decline in mucociliary transport efficiency, reduced surfactant homeostasis, and diminished capacity for bronchial epithelial repair. At the molecular level, these changes correlate with declining expression of key transcription factors including NKX2-1 and FOXA2, reduced secretoglobin production, and impaired goblet and club cell function.

The gene targets identified in Bronchogen research — NKX2-1, FOXA1/2, SCGB1A1, SCGB3A2, MUC4, MUC5AC, SFTPA1 — map precisely onto this aging transcriptional decline. The finding that AEDL's proliferative effects are strongest in aged cell cultures reinforces the hypothesis that this class of bioregulators may be particularly relevant to research into lung senescence and regenerative biology.

Within the Khavinson research framework, Bronchogen complements other bioregulators already characterized for lung-adjacent systems. Thymosin Alpha 1 addresses the immunological dimension of pulmonary defense, while VIP (Vasoactive Intestinal Peptide) has been studied for airway smooth muscle tone and pulmonary vasodilation. Bronchogen's unique contribution is its tissue-specific program focused on bronchial epithelial gene expression and cellular identity maintenance.

---

Comparison with Other Respiratory Research Peptides

Bronchogen occupies a unique mechanistic space: while BPC-157 modulates healing via growth factor pathways and LL-37 engages membrane-based antimicrobial mechanisms, Bronchogen operates at the transcriptional level — activating the gene expression programs that define bronchial epithelial identity and function.

---

Research Considerations

Source and Purity

For research applications, Bronchogen is commercially available from several peptide synthesis companies at purity levels ≥99% by HPLC. As with all research peptides, researchers should obtain documentation including certificate of analysis (COA), HPLC chromatograms, and mass spectrometry confirmation of molecular identity prior to experimental use. See the site's guide on how to verify peptide purity for a complete methodology.

Storage Parameters

AEDL is a thermostable peptide (as evidenced by its DNA-stabilizing properties), but standard research peptide storage practices apply: lyophilized powder should be stored at -20°C and protected from moisture. Reconstituted solutions should be aliquoted and stored at -80°C for extended stability. Avoid repeated freeze-thaw cycles. Consult the site's peptide degradation and storage guide for detailed protocols.

Experimental Concentrations

Published cell culture experiments utilized AEDL at 10⁻⁷ M (100 nM), a concentration range appropriate for receptor-independent bioregulatory effects and consistent with physiologically relevant signaling peptide concentrations in bronchial epithelial models. DNA-binding studies utilized molar ratios of 0.01–0.055 relative to DNA.

Research Limitations

The scientific literature on Bronchogen remains predominantly preclinical and in vitro. Most foundational studies originate from Khavinson's group in Russia, and independent replication in Western academic research settings is limited. Studies have largely used cell culture models and plant systems; rigorous randomized controlled investigation has not been conducted. These limitations are inherent to the early research stage of this compound and should be weighed carefully when designing experimental programs.

---

Sourcing Context

Bronchogen is commercially available from multiple research peptide suppliers in 20 mg lyophilized vials. As the Khavinson bioregulator class has gained recognition in longevity and aging research communities, availability has expanded significantly since 2020. Researchers should prioritize suppliers providing third-party testing from accredited analytical laboratories. For a framework on evaluating supplier reliability, see the guide to peptide supplier red flags.

---

Summary

Bronchogen (AEDL) is the bronchopulmonary member of the Khavinson tetrapeptide bioregulator family. Its research profile is defined by:

• •Tissue-specific gene regulation: Activation of NKX2-1, FOXA1/2, SCGB1A1, SCGB3A2, MUC4, MUC5AC, and SFTPA1 in bronchial epithelial cell systems
• •Epigenetic mechanism: Chromatin decondensation via direct histone binding (H1, H3) and DNA major groove interaction
• •DNA stabilization: Demonstrated thermostabilizing effects on double-stranded DNA at nanomolar concentrations
• •Immunomodulatory dimension: Related bioregulatory peptides in the bronchial class show TNF inhibition in macrophage models
• •Geroprotective potential: Strongest proliferative effects observed in aged bronchial cell cultures

For laboratory researchers investigating pulmonary aging, bronchial epithelial biology, mucociliary physiology, or the epigenetics of airway disease, Bronchogen represents an understudied but well-characterized tool with a coherent mechanistic profile backed by peer-reviewed evidence. Its mechanism of action — operating at the chromatin and transcription level rather than through surface receptor pharmacology — positions it as a complementary research instrument to conventional growth factor and receptor-targeting approaches in lung biology.

---

All peptides described on this platform are research chemicals for laboratory use only. This content is for educational and scientific reference purposes. No clinical or therapeutic claims are made.